EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension

Akira Sezai iD, Msasnori Abe iD, Takashi Maruyama, Makoto Taoka, Hisakuni Sekino, Masashi Tanaka

Life · 05.05.2025 · 15 (5) · 741

DOI: 10.3390/life15050741 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 05.05.2025. Verfasst von Akira Sezai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone’s efficacy in treating chronic heart failure. This crossover study compared esaxerenone with eplerenone, an approved treatment for heart failure, in 66 patients with chronic heart failure complicated by hypertension (12 months for each drug). The primary endpoint was brain natriuretic peptide. The secondary endpoints included blood pressure; hormones and enzymes that regulate electrolytes and stress response; and biomarkers of kidney function. Change in brain natriuretic peptide concentration was significantly lower for esaxerenone compared with eplerenone at 3, 6, and 12 months. Blood pressure (all time points), plasma aldosterone concentration (3 and 6 months), and urinary albumin-to-creatinine ratio (3 and 6 months) were significantly lower for esaxerenone compared with eplerenone. The results suggest that esaxerenone more strongly blocks aldosterone binding than does eplerenone. This effect, together with its strong antihypertensive effect and reduced urinary albumin-to-creatinine ratio, suggests that esaxerenone improves kidney function. The results of this small-scale, single-center study need to be expanded to a larger-scale investigation, but esaxerenone shows promise as a treatment for chronic heart failure with hypertension.

Schlagwörter

Stichwörter der Autor:innen

chronic heart failureeplerenoneesaxerenoneheart failuremineralocorticoid receptor antagonist

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan.
  • Division of Nephrology, Hypertension, and Endocrinology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan.
  • Sekino Hospital, 3-28-3, Ikebukuro, Toshima-ku, Tokyo 171-0014, Japan.

ORCID-Profile: Akira Sezai, Msasnori Abe

Zitieren

APA

Sezai, A., Abe, M., Maruyama, T., Taoka, M., Sekino, H., & Tanaka, M. (2025). A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension. Life, 15(5), 741. https://doi.org/10.3390/life15050741

Vancouver

Sezai A, Abe M, Maruyama T, Taoka M, Sekino H, Tanaka M. A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension. Life. 2025;15(5):741. doi:10.3390/life15050741

BibTeX
@article{Sezai2025,
  author = {Sezai, Akira and Abe, Msasnori and Maruyama, Takashi and Taoka, Makoto and Sekino, Hisakuni and Tanaka, Masashi},
  title = {A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {5},
  pages = {741},
  doi = {10.3390/life15050741}
}
Kostenlos starten →